Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Approved for marketing 1

Sponsor Class

OTHER 2

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Osteosarcoma 6Lymphoma 4Renal Insufficiency 3Neurotoxicity Syndromes 2Neoplasms 2Mucositis 2Lymphoma, Large B-Cell, Diffuse 2Leukemia 2Hematologic Neoplasms 2Drug-Related Side Effects and Adverse Reactions 2Water Intoxication 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Acute Kidney Injury 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 98Fluorouracil 90Capecitabine 86Dexamethasone 81Radiotherapy 80Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Leucovorin 64Drug Therapy 64Cetuximab 60Erlotinib Hydrochloride 56Sorafenib 53atezolizumab 52Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × glucarpidase × Clear all
NCT00219791 2014-09-11

Study of Glucarpidase (CPG2) for the Management of Patients With Delayed Methotrexate Clearance

BTG International Inc.

Phase 2 Completed

Neoplasms, Renal Insufficiency

NCT00481559 2014-01-17

Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity

BTG International Inc.

Approved for marketing
LymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Neoplasms, Osteosarcoma, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡